» Articles » PMID: 36875101

Ongoing Involvers and Promising Therapeutic Targets of Hepatic Fibrosis: The Hepatic Immune Microenvironment

Overview
Journal Front Immunol
Date 2023 Mar 6
PMID 36875101
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic fibrosis is often secondary to chronic inflammatory liver injury. During the development of hepatic fibrosis, the damaged hepatocytes and activated hepatic stellate cells (HSCs) caused by the pathogenic injury could secrete a variety of cytokines and chemokines, which will chemotactic innate and adaptive immune cells of liver tissue and peripheral circulation infiltrating into the injury site, mediating the immune response against injury and promoting tissue reparation. However, the continuous release of persistent injurious stimulus-induced inflammatory cytokines will promote HSCs-mediated fibrous tissue hyperproliferation and excessive repair, which will cause hepatic fibrosis development and progression to cirrhosis even liver cancer. And the activated HSCs can secrete various cytokines and chemokines, which directly interact with immune cells and actively participate in liver disease progression. Therefore, analyzing the changes in local immune homeostasis caused by immune response under different pathological states will greatly enrich our understanding of liver diseases' reversal, chronicity, progression, and even deterioration of liver cancer. In this review, we summarized the critical components of the hepatic immune microenvironment (HIME), different sub-type immune cells, and their released cytokines, according to their effect on the development of progression of hepatic fibrosis. And we also reviewed and analyzed the specific changes and the related mechanisms of the immune microenvironment in different chronic liver diseases.Moreover, we retrospectively analyzed whether the progression of hepatic fibrosis could be alleviated by modulating the HIME.We aimed to elucidate the pathogenesis of hepatic fibrosis and provide the possibility for exploring the therapeutic targets for hepatic fibrosis.

Citing Articles

The effect and application of adiponectin in hepatic fibrosis.

Chen T, Yang W, Dong R, Yao H, Sun M, Wang J Gastroenterol Rep (Oxf). 2024; 12:goae108.

PMID: 39737222 PMC: 11683834. DOI: 10.1093/gastro/goae108.


Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.

Yang J, Zhang Z, Pang C, Cao D, Yan D, Fan J Transl Oncol. 2024; 48:102071.

PMID: 39098213 PMC: 11359764. DOI: 10.1016/j.tranon.2024.102071.


A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular Carcinoma.

Wu J, Liu W, Qiu X, Li J, Song K, Shen S Phenomics. 2024; 3(6):549-564.

PMID: 38223688 PMC: 10781918. DOI: 10.1007/s43657-023-00136-8.

References
1.
Rao J, Wang H, Ni M, Wang Z, Wang Z, Wei S . FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2. Gut. 2022; 71(12):2539-2550. PMC: 9664121. DOI: 10.1136/gutjnl-2021-325150. View

2.
Zhu H, Liu Z, An J, Zhang M, Qiu Y, Zou M . Activation of AMPKα1 is essential for regulatory T cell function and autoimmune liver disease prevention. Cell Mol Immunol. 2021; 18(12):2609-2617. PMC: 8632917. DOI: 10.1038/s41423-021-00790-w. View

3.
Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

4.
Park J, Shao M, Kim M, Baik S, Cho M, Utsumi T . An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology. 2017; 65(5):1720-1734. PMC: 5397326. DOI: 10.1002/hep.29051. View

5.
Khan H, Ahmad M, Khan J, Arshad M . Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance. Hepatobiliary Pancreat Dis Int. 2017; 16(3):245-256. PMC: 7172563. DOI: 10.1016/s1499-3872(17)60014-6. View